Quest Pharmatech's Madenco creates cosmecutical line
2017-05-18 08:35 ET - News Release
Dr. Madi Madiyalakan reports
MADENCO BIOSCIENCES CREATES NEW LINE OF COSMECEUTICALS TO COMPLEMENT BELLUS SKIN SERUM FOR ANTI-AGING
Madenco Biosciences Inc., a subsidiary of Quest Pharmatech Inc., has created the SP-DERM line of cosmeceuticals specifically targeting applications that are demanded by dermatologists and medi-spas.
The SP-DERM line is based on Madenco's proprietary SP-Technology platform that creates topically deliverable molecules with superior properties in terms of skin permeability or topical absorption. These molecules are also known as protein transduction domain (PTD) or cell-penetrating peptides/proteins (CPP).
Utilizing SP-Technology and with guidance from Dr. Jaggi Rao, MD, FRCPC, a respected Edmonton dermatologist and cosmetic surgeon, the following three products will mark the entry of the SP-DERM line: (i) SP-DERM Recovery, a postprocedural cream for promoting recovery after intensive laser treatments and/or other procedures that leave the skin barrier compromised; (ii) SP-DERM Maintenance, a maintenance cream for prolonging the effects of cosmetic procedures; and (iii) SP-DERM Acne, a serum to minimize the appearance of acne scars.
A preliminary pilot study in patients suffering from acne scars treated with SP-DERM Acne demonstrated improvement in both doctor assessed and self-assessed results after four weeks and eight weeks of treatment with SP-DERM Acne.
"The result of this pilot study with SP-DERM Acne is encouraging and warrants further controlled clinical study," said Dr. Rao. "If proven, SP-DERM Acne could offer a unique effective therapeutic solution to millions of acne sufferers."
"We are excited to collaborate with Dr. Rao to introduce scientifically developed cosmeceuticals to dermatologists," said Dr. Madi Madiyalakan, chief executive officer of Madenco/Quest. "SP-DERM will fill a much-needed market niche as there is no current standard for postprocedural treatment or for acne scar treatment in dermatology clinics. With over $12-billion spent annually on cosmetic procedures in the U.S., there is a huge market potential for products like SP-DERM that can enhance the benefits of cosmetic treatment in dermatology clinics and spas as we continue to explore other indications."
Madenco has previously introduced Bellus Skin serum to the Canadian market, a clinically validated anti-aging skin serum proven to reduce the appearance of wrinkles and signs of aging using SP-Technology to deliver fusion proteins targeting growth factors into the skin. Bellus Skin serum is available for purchase on-line at the Bellus website.
Madenco has also entered into sale agreements for Bellus Skin serum in the European Union with a Swiss-based company called HCBD AG and for ASEAN countries with a Singapore-based company, Merhati-Innokeys, and is preparing its first shipment of product to Singapore this month.
About Quest Pharmatech Inc.
Quest Pharmatech is a publicly traded, Canadian-based pharmaceutical company developing products to improve the quality of life. The company, through its subsidiary, OncoQuest, is developing antibody-based immunotherapeutic products for cancer. In addition, the company owns the photodynamic therapy technology for oncology and dermatology applications, licensed to BioCeltran Co. Ltd., a Korea-based company. Quest also markets consumer health products worldwide, including Bellus Skin serum, a premium anti-wrinkle skin care product licensed from Korea.
© 2017 Canjex Publishing Ltd. All rights reserved.